Cullinan Therapeutics Licensing of velinotamig (BCMAxCD3) from Genrix Bio June 2025 © CULLINAN THERAPEUTICS, INC. ALL RIGHTS RESERVED. CONFIDENTIAL AND PROPRIETARY Important Notice and Disclaimers This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Cullinan's beliefs and expectations regarding the potential benefits of, and pl ...

Core Insights - Cullinan Therapeutics has advanced its leadership in T cell engager (TCE) development for autoimmune diseases, with both a CD19 TCE and BCMA TCE in its pipeline [1] - The company has strengthened its portfolio of autoimmune programs, aiming to address a broader range of diseases while ensuring cash runway into 2028 [1][5] - Cullinan has entered into an agreement with Genrix Bio for an exclusive global license to velinotamig, a BCMAxCD3 bispecific T cell engager, which has shown promising efficacy in treating relapsed/refractory multiple myeloma [2][3] Company Developments - Velinotamig has demonstrated potential best-in-class efficacy at the Phase 2 target dose in nearly 50 patients with relapsed/refractory multiple myeloma [2] - The agreement includes an upfront license fee of $20 million, with potential future payments of up to $292 million in development and regulatory milestones, plus up to $400 million in sales-based milestones [4] - Cullinan plans to leverage data from Genrix's Phase 1 study in China to accelerate global clinical development of velinotamig in autoimmune diseases [3][4] Industry Context - T cell engagers are viewed as the next wave of innovation in autoimmune diseases, with BCMA as a promising target for a precise and potentially disease-modifying approach [3] - The collaboration with Genrix Bio is expected to enhance Cullinan's capabilities in developing therapies for autoimmune diseases, addressing the needs of a wider patient population [4][10]

Summary of the Conference Call on Cell Therapy and Autoimmune Diseases Industry Overview - The discussion focuses on the emerging field of cell therapy, particularly T cell engagers and CAR T therapies, and their applications in treating autoimmune diseases alongside oncology applications [1][2]. Key Companies and Their Innovations Cullinan - Cullinan is exploring T cell engagers to redirect T cells for depleting aberrant immune cells, particularly B cells, in autoimmune diseases [3]. - The company aims to make T cell redirecting therapies accessible in community-based centers, enhancing patient access [3]. Autolus - Autolus has launched a CD19 CAR T product approved for acute leukemia, demonstrating a strong safety profile and exceptional activity, leading to long-term remissions in advanced disease patients [4][5]. - The company is also looking to expand into the autoimmune space, believing that their product's features will be beneficial [6]. Caballetta - Caballetta focuses on developing cellular therapies specifically for autoimmune diseases, with their lead product ResiCel entering phase three trials for myositis [9][10]. - The company has agreements with the FDA for multiple cohorts in various trials, targeting diseases like lupus and multiple sclerosis [11]. Core Insights and Arguments - The panelists agree on the significant unmet need in autoimmune diseases and the potential for their therapies to provide meaningful clinical advances [8]. - T cell engagers have shown promise in achieving disease-modifying benefits, with reports indicating deep B cell depletion and symptom improvement in treated patients [14][15]. - The safety profile of these therapies is emphasized as a key differentiator in a market with high unmet needs [11][12]. Clinical Development and Regulatory Pathways - The discussion highlights the importance of understanding patient subtypes and tailoring treatment strategies based on disease severity and pathology [41]. - There is a consensus that the regulatory path for T cell engagers may differ from traditional drug approvals, with a focus on therapeutic benefit and safety [63][64]. Market Dynamics and Future Outlook - The panelists predict a competitive landscape in the autoimmune therapy market, with multiple modalities coexisting rather than competing fiercely [13]. - The potential for bispecific therapies to transform treatment paradigms is acknowledged, with expectations for improved efficacy and safety profiles [32][38]. - The market for autoimmune therapies is seen as distinct from oncology, with different pricing and patient demographics influencing market strategies [30][31]. Additional Considerations - The importance of biomarkers in identifying suitable patients for different therapies is highlighted, with ongoing research expected to refine patient selection [25][41]. - The need for collaboration between hematologists and rheumatologists is emphasized to facilitate patient enrollment in clinical trials [58][61]. This summary encapsulates the key points discussed during the conference call, providing insights into the current state and future potential of cell therapies in treating autoimmune diseases.

Financial Data and Key Metrics Changes - The company reported approximately $570 million in cash, providing a runway into 2028 based on the current operating plan [7] - The overall response rate in the RESILIENT-one study was 35%, with a 40% response rate in patients who progressed after chemotherapy [17][18] - The median duration of response was just under nine months across all groups [18] Business Line Data and Key Metrics Changes - The company is advancing multiple clinical-stage programs, including CLN978 for autoimmune diseases and CLN619 for non-small cell lung cancer [6] - Zipilertinib, the oral EGFR tyrosine kinase inhibitor, has shown promising results in patients with EGFR exon 20 mutations, with breakthrough therapy designation by the FDA [11][12] Market Data and Key Metrics Changes - EGFR mutated non-small cell lung cancer accounts for 16% of all non-small cell lung cancer, with exon 20 mutations representing approximately 12%, translating to an annual incidence of about 3,000 to 5,000 patients in the U.S. [67] - The company noted that patients with exon 20 mutations tend to have a poorer prognosis, highlighting the unmet need for effective therapies [68] Company Strategy and Development Direction - The company plans to pursue regulatory interactions for a potential U.S. NDA filing in the second half of the year [22][23] - There is an expansive development program for zipilertinib across multiple patient segments, including relapsed refractory disease and frontline settings [69][70] - The company retains 50% of the rights for zipilertinib in the U.S. and has a co-development and co-commercialization arrangement with partners at Tahoe [77][78] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical profile of zipilertinib, noting its favorable safety profile compared to existing therapies [75] - The company anticipates significant uptake of zipilertinib once it becomes available, particularly as an oral option for patients [60][62] Other Important Information - The RESILIENT-two study will provide data on patients with active brain metastases and those with uncommon EGFR mutations in the second half of the year [79] - The RESILIENT-three study is ongoing, comparing zipilertinib plus chemotherapy to standard care [72] Q&A Session Summary Question: What is the efficacy of zipilertinib in patients with brain metastases? - The drug has shown encouraging preliminary data in patients with brain metastases, with good disease control observed [84][86] Question: What is the breakdown of patients in real-world settings? - Most patients are heavily pretreated, often having received chemotherapy and amivantamab before seeking other options [88][90] Question: Is there any data on the role of MET amplification in exon 20? - The response to this question was not directly addressed in the provided content, indicating a need for further research [94]

Core Insights - Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced positive results from the REZILIENT1 trial for zipalertinib in treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations [1][4] - The trial results will be presented at the 2025 ASCO Annual Meeting [1] Company Overview - Taiho Oncology specializes in developing and commercializing orally administered anti-cancer agents, focusing on solid tumors and hematological malignancies [9] - Cullinan Therapeutics is dedicated to creating new standards of care in cancer and autoimmune diseases, with a diversified portfolio of clinical-stage assets [11] Clinical Trial Details - REZILIENT1 is a Phase 1/2 global study evaluating the efficacy and safety of zipalertinib in patients with advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations [5] - The primary endpoints of the trial were overall response rate (ORR) and duration of response (DOR) [5] Efficacy Results - Zipalertinib demonstrated a confirmed ORR of 35.2% overall, with a median DOR of 8.8 months and progression-free survival of 9.4 months [8] - In patients who received prior platinum-based chemotherapy, the ORR was 40% with a median DOR of 8.8 months [8] - Subgroup analyses showed a confirmed ORR of 30% and median DOR of 14.7 months in patients who had prior amivantamab [8] Safety Profile - The safety profile of zipalertinib was manageable and consistent with previously reported data [8]

Company Overview - Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies across various modalities for autoimmune diseases and cancer [3] - The company has built a diversified portfolio of clinical-stage assets aimed at inhibiting key disease drivers and harnessing the immune system [3] - Cullinan aims to create new standards of care by identifying optimal targets and developing transformative therapeutics [3] Upcoming Events - The management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL [1] - An in-person event for analysts and institutional investors is scheduled for June 1, 2025, at 6:30 p.m. CT, following the oral presentation of results from the pivotal Phase 2b REZILIENT1 trial [4] - Participation in the Jefferies 2025 Global Healthcare Conference will include a panel discussion on June 4, 2025, and a company presentation on June 5, 2025 [4] Investor Relations - Webcasts of the ASCO event and Jefferies Conference presentations will be available on the company's investor relations website [2] - Investors and analysts can register for the in-person event by contacting the Head of Investor Relations [4]

Core Insights - Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology announced positive results from the Phase 2b cohorts of the REZILIENT1 trial for zipalertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations [1][2] Efficacy Results - A total of 244 patients were enrolled in the REZILIENT1 trial, with 176 patients included in the overall efficacy population, showing a confirmed overall objective response rate (ORR) of 35% and a median duration of response (mDOR) of 8.8 months [3][7] - In patients who had received prior platinum-based chemotherapy, the ORR was 40% with an mDOR of 8.8 months [7] - For patients with prior chemotherapy and amivantamab, the ORR was 30% with an mDOR of 14.7 months [7] - Patients with brain metastases had an ORR of 31% with an mDOR of 8.3 months [7] Safety and Tolerability Results - Zipalertinib demonstrated a manageable safety profile, with the most common treatment-related adverse events (TRAEs) being paronychia (38.5%), rash (30.3%), and dermatitis acneiform (24.6%) [4][5] - The majority of TRAEs were grade 1 or 2, with grade ≥3 TRAEs including anemia (7%) and pneumonitis (2.5%) [5][4] About Zipalertinib - Zipalertinib is an orally available small molecule targeting EGFR mutations, specifically designed to inhibit EGFR variants with exon 20 insertion mutations while sparing wild-type EGFR [7][8] - It has received Breakthrough Therapy Designation from the FDA and is currently investigational [8] About EGFR Exon 20 Insertion Mutations - EGFR exon 20 insertions account for up to 4% of all NSCLC cases, making them the third most common EGFR mutation subtype [9]

Financial Position - As of March 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $303.8 million, with long-term investments and interest receivable of $263.6 million[77]. - The company has an accumulated deficit of $416.7 million as of March 31, 2025, and expects to continue generating operating losses for the foreseeable future[77]. - As of March 31, 2025, the company had net cash used in operating activities of $43.2 million, an increase from $38.2 million in the same period of 2024, reflecting higher operating expenses[93][94][95]. - The company has received net proceeds of $842.2 million from equity financings since its inception in 2016[76]. - The company has an at-the-market equity offering program allowing for the sale of up to $125.0 million in common stock, with $85.6 million remaining as of March 31, 2025[92]. - The company has sold approximately 3.3 million shares under the ATM program, receiving net proceeds of $38.4 million after commissions[92]. Operating Performance - The company reported a net loss of $48.5 million for the three months ended March 31, 2025, compared to a net loss of $37.3 million for the same period in 2024, reflecting an increase in operating expenses[84]. - Research and development expenses increased by $10.8 million to $41.5 million for the three months ended March 31, 2025, primarily due to higher clinical costs and personnel costs[86]. - The company has not generated any revenue from product sales since its inception and does not expect to do so in the near future[80]. - The company expects to incur significant expenses related to product manufacturing and commercialization as it progresses with its development programs[99]. Clinical Development - The Phase 2b portion of the REZILIENT1 trial for zipalertinib met its primary endpoint, with results to be presented at the 2025 ASCO Annual Meeting[71]. - The company plans to initiate a Phase 1 clinical trial for CLN-978 in patients with Sjögren's disease in the second quarter of 2025[70]. - CLN-619's development in gynecological cancers has been discontinued due to preliminary results not meeting internal advancement thresholds[71]. Future Outlook - Future funding requirements are expected to increase significantly due to ongoing development programs and regulatory review processes, necessitating potential additional capital for product manufacturing and commercialization[99][101]. - Total future minimum lease payments as of March 31, 2025, were $2.0 million, with $1.5 million due within twelve months[103]. Market and Economic Conditions - The company has not experienced significant market risk related to foreign currency exchange rates but may face increased risk with future contracts with international vendors[109]. - Inflation has not had a material effect on the company's business or financial condition during the three months ended March 31, 2025[110]. Financing Activities - The company has no cash provided by financing activities for the three months ended March 31, 2025, compared to $1.1 million in 2024 from equity-based compensation plans[98].

Clinical Trials and Approvals - Cullinan Therapeutics received EMA approval for CLN-978; Phase 1 study in difficult-to-treat rheumatoid arthritis to start in Q2 2025[1] - The company plans to initiate a Phase 1 study for CLN-978 in Sjögren's disease in the U.S. in Q2 2025[1] - The pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib met the primary endpoint of overall response rate[3] - The company expects to deliver initial clinical data in systemic lupus erythematosus by the end of 2025[2] - CLN-619 development in gynecological cancers has been discontinued due to preliminary results not meeting internal advancement thresholds[6] Financial Performance - Cash position as of March 31, 2025, was $567.4 million, providing a runway into 2028[9] - Research and development expenses for Q1 2025 were $41.5 million, up from $30.6 million in Q1 2024[9] - General and administrative expenses for Q1 2025 were $13.5 million, compared to $12.3 million in Q1 2024[9] - Net loss attributable to Cullinan for Q1 2025 was $48.5 million, compared to $37.1 million in Q1 2024[9] - Total operating expenses for Q1 2025 were $55.0 million, compared to $43.0 million in Q1 2024[9]

Core Insights - Cullinan Therapeutics has received approval from the European Medicines Agency (EMA) for CLN-978, with Phase 1 studies in rheumatoid arthritis and Sjögren's disease set to begin in Q2 2025 [1][6] - The company is advancing its clinical development of CLN-978 across multiple autoimmune diseases and expects to share initial clinical data in systemic lupus erythematosus (SLE) by the end of 2025 [2] - The pivotal Phase 2b study of zipalertinib has met its primary endpoint, with results to be presented at the 2025 ASCO Annual Meeting [3] Immunology - CLN-978 is being developed for systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's disease, with ongoing Phase 1 studies in the U.S., Europe, and Australia [6] - The company plans to initiate a Phase 1 study for active, difficult-to-treat rheumatoid arthritis in Germany and Italy in Q2 2025 [6] - A Phase 1 study for active, moderate to severe Sjögren's disease is also set to begin in the U.S. in Q2 2025 [6] Oncology - The pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib has met the primary endpoint of overall response rate in patients with EGFR ex20ins NSCLC [3][6] - The company plans to submit a New Drug Application (NDA) for relapsed/refractory EGFR ex20ins NSCLC in the second half of 2025 [6] - Development of CLN-619 in gynecological cancers has been discontinued due to preliminary results not meeting internal advancement thresholds [6] Financial Performance - As of March 31, 2025, the company reported cash and investments totaling $567.4 million, providing a runway into 2028 [3][11] - Research and development expenses for Q1 2025 were $41.5 million, up from $30.6 million in Q1 2024 [11][14] - The net loss attributable to Cullinan for Q1 2025 was $48.5 million, compared to $37.1 million for the same period in 2024 [11][14]